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COVID-19 mRNA vaccine booster cutaneous reactions reported to the
AAD/ILDS dermatology registry
S Prasad1, DE McMahon1, A Tyagi1, R Singh1, R Ali1, HW Lim3, LP Fox2, K Blumenthal1, G
Hruza4, LE French5 and E Freeman1 1 Massachusetts General Hospital, Boston, Massachusetts, United States, 2 University of California San Francisco, San Francisco, California,
United States, 3 Henry Ford Health System, Detroit, Michigan, United States, 4 Saint Louis
University, Saint Louis, Missouri, United States and 5 Ludwig-Maximilians-Universitat
Munchen, Munchen, Bayern, Germany
Background:In summer 2021, several countries including the U.S. authorized COVID-19 mRNA
vaccine booster doses 6 months after completion of a patient’s primary vaccine series. The aim
of this study was to characterize vaccine cutaneous reactions following a booster dose of mRNA
vaccine reported to the American Academy of Dermatology (AAD) & International League of
Dermatologic Societies (ILDS) COVID-19 Dermatology registry. Methods:In December 2020,
the AAD/ILDS registry was adapted to include COVID-19 vaccine skin reactions. In September
2021 the registry also solicited COVID-19 vaccine booster reactions either as new cases or
updates to existing entries. Results:From Dec 2020-Jan 2022, 994 cases of vaccine skin reactions
were entered in the registry, of which 44 records indicated the presence or absence of cutaneous
reactions following a booster dose. Of 44 records, 31(71%) developed a cutaneous reaction to
the booster dose and 29% developed a reaction to the 1st and/or 2nd dose but not the booster.
Of the 31 patients who developed a reaction to the booster dose, 22 reacted to the booster alone,
1 reacted to the 1st & booster, 3 reacted to the 2nd & booster, and 5 reacted to all three doses.
The most common morphologies among all booster reactions were local injection site reactions
(n¼31), delayed large local reaction (n¼7), erythromelalgia (n¼3), and vesicular reactions
(n¼3). Conclusion:Booster reactions represent a small portion of COVID vaccine reactions in the
registry. Infrequent reporting could be due slow booster uptake, reporter fatigue, and/or booster
reactions may truly be less frequent than reactions to the initial series. Dermatologists should be
aware that cutaneous reactions to boosters are possible, even when reactions to dose 1 & 2 did
not occur;none of the reactions were life-threatening.

Poor validity of hidradenitis suppurativa diagnostic criteria in pediatric
patients
JC Williams, NW Kittler, MV Kudlinski, J Lester, K Abuabara and HB Naik Dermatology,
University of California San Francisco, San Francisco, California, United States
Although HS commonly presents in adolescence, diagnostic criteria have not been validated
in children. This study aimed to determine the proportion of pediatric patients who met HS
diagnostic criteria at time of diagnosis. We conducted a single-center retrospective chart
review of pediatric patients identified by HS ICD-9/10 code from January 1, 2012eJuly 1,
2021. We collected data on demographics and fulfillment of major diagnostic criteria: (1)
typical lesion, 2) typical location, 3) recurrence (>2 flares in past 6 months)). We present
descriptive statistics as proportions and fisher’s exact tests. 296 patient records were included
in the study. The majority were female (78.1%), Latinx (39.2%), and Black (18.9%). Median
age at disease onset was 14 years (IQR 12-16 years). 55.1% (N¼163) of patients were
documented to have met all three diagnostic criteria at diagnosis. 96.0% (121/126) of patients
who did not meet all criteria failed to meet the recurrence criterion. 79.3% (96/121) of patients who did not meet the recurrence criterion at diagnosis had additional visit records that
were examined for flare frequency. Additional lesions consistent with HS were documented
in 68 patients. Of 28 patients who had 1 lesion consistent with HS before their diagnostic
visit, 10 had a documented lesion within a 6-month interval. With these additional data,
diagnostic criteria were actually fulfilled in 58.4% (173/296) of patients at the time of
diagnosis. Of 40 patients who had 1 lesion consistent with HS after their diagnostic visit, 33
(82.5%) had lesions within a 1-year period. Patients who did not meet major diagnostic
criteria were less likely to have ever received a diagnosis by dermatology (34.1% vs 55.0% p
< 0.001). Over 40% of pediatric HS patients do not meet all major diagnostic criteria. Many
pediatric patients experience disease recurrence at a longer interval, suggesting that this
criterion may be too strict for the pediatric population.

Non-melanoma skin cancer and hereditary hemochromatosis: A retrospective
cohort study
CX Pan1,2, K Yang1,3, CB Lau1,4, G Zhou1 and V Nambudiri1,2 1 Brigham and Women’s
Hospital, Boston, Massachusetts, United States, 2 Harvard Medical School, Boston, Massachusetts, United States, 3 Tufts Medical Center, Boston, Massachusetts, United States and
4 Boston University, Boston, Massachusetts, United States
Hereditary hemochromatosis (HH) is a genetic disease of altered iron homeostasis. HH
causes skin hyperpigmentation and various diseases, such as hepatocellular carcinoma via
oxidative stress. Although oxidative damage also plays a role in the pathogenesis of nonmelanoma skin cancer (NMSC), the link between HH and NMSC remains unknown. Data on
HH patients with skin neoplasms and controls from 1980 to 2021 matched by age, sex, and
race were extracted. HH carriers without disease and/or those without pathology-proven skin
neoplasms were excluded. Univariate and multivariate regression analyses (adjusted for age,
sex, skin type, smoking history, and NMSC risk factors) were conducted. Among 321 HH
patients and 374 controls, HH patients (92%) had significantly higher rates of NMSC than
controls (83.4%) (adjusted odds ratio (OR), 2.08 [95%CI, 1.26, 3.43], P¼ 0.004). When
stratified by NMSC type, HH patients had significantly greater odds of having basal cell
carcinoma (BCC) than controls (adjusted OR, 1.93 [95%CI, 1.39, 2.69], P<0.001). There
were no significant differences in age at diagnosis (P¼ 0.086), mean number of NMSCs
(P¼0.129), or rates of squamous cell carcinoma (SCC) (P¼ 0.077). A subset analysis of HH
patients with NMSC by phlebotomy treatment status showed that treated patients had
significantly higher rates of NMSCs (P<0.001) and were diagnosed at a younger age
compared to the untreated group (P<0.034). Notably, there were no significant differences in
rates of BCCs and SCCs when stratified by NMSC type. Our findings suggest that HH may be a
risk factor for NMSCs, particularly BCCs, potentially warranting increased skin cancer surveillance among HH patients. Phlebotomy treatment does not appear to be protective against
NMSCs and may be associated with confounders, such as greater interaction with the
healthcare system, requiring further analysis.

International survey: Effects of cumulative exposure to corticosteroids in
patients with eczema, including topical steroid withdrawal syndrome (TSWS)
KZ Tullos2, K Barta1, P Lio3 and T Winders4,5 1 Advocacy, Allergy and Asthma Network,
Vienna, Virginia, United States, 2 International Topical Steroid Awareness Network, Dacula,
Georgia, United States, 3 Dermatology and Pediatrics, NYU Langone Hospital - Long Island,
Mineola, New York, United States, 4 President, Allergy and Asthma Network, Vienna,
Virginia, United States and 5 Global Allergy and Airways Patient Platform, VIENNA, Virginia, United States
Patients with eczema have a lifetime of exposure to corticosteroids (topical (TCS), oral (OCS),
inhaled, nasal sprays etc). The survey examined cumulative effects of corticosteroid exposure,
sociodemographic characteristics, disease attributes, history of eczema treatment, and
experience and knowledge of topical steroid withdrawal syndrome (TSWS). Surveyed total
lifetime corticosteroid use of all types. 91% reported TCS use with an average duration of
15.3 years, applying 1-2 times daily, for 15-30 days a month, on an average body surface area
(BSA) of 24%. Adult and child body diagram was used to assess eczema symptom location
and severity from the PO-SCORAD tool, and to determine % of BSA where TCS were used
most often. OCS for eczema or other conditions was 36%, with an average of 8 OCS courses
during their lifetime. Adults (83%) and children (64%) had new and/or worsening symptoms
overtime. A description of TSWS was included - 79% of adults and 43% of children had
symptoms consistent with TSWS. Body diagram assessed TSWS BSA, symptoms, and severity.
Over 90% of all adults with TSWS report burning, skin shedding/profuse flaking, and flushing
or darkening depending on skin tone. Survey distribution was by email or social media to
patients by patient organizations and panels between 11/2020e1/2021, and completed by
those 18 years of age and older diagnosed with eczema or a caregiver of a child with eczema.
All participants (n¼2,160) completed the survey; 87.4% were adults while 12.5% were
caregivers of children. Respondents were from 70 countries; 85% of adults were female; 55%
of the children were male. Cumulative corticosteroid exposure over a lifetime of eczema is
substantial and associated with development of new conditions, including TSWS.
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Epidemiology and survival of merkel cell carcinoma by sex in the United States
IH Moseley1, SD Ragi1 and A Lombardi2 1 Brown University Warren Alpert Medical School,
Providence, Rhode Island, United States and 2 Skin Cancer & Cosmetic Surgery Center of
New Jersey, Edison, New Jersey, United States
Introduction: Merkel Cell Carcinoma (MCC) is a rare, aggressive skin cancer with a known
male predominance. However, it is unknown whether tumor presentation, age of presentation, or prognosis varies by sex. We analyzed data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEERs) Program to investigate these questions.
Methods: Data for MCC were collected from the SEER-18 (2000-2018) database. The total
number of cases, incidence, age, race, ethnicity, primary tumor location, staging, causespecific death, and first malignancy status were collected in SEER*Stat. We used traditional
chi-squared or Fisher exact tests to compare the aforementioned variables between sexes. We
calculated relative survival by the KaplaneMeier method. Rates are per 100,000 and ageadjusted to the 2000 US Std Population. Results: In the SEER data set, MCC had an incidence
rate of 0.616 (95% CI 0.604-0.628), 0.943 (95% CI 0.919-0.967) in men, and 0.390 (95% CI
0.377-0.403) in women. Significant differences between sexes (p <0.05) were observed for:
age, race, ethnicity, location, staging, first malignancy status, and disease-specific death.
Survival rates at 1, 3, & 5 years also differed significantly by sex. 76.80% of men & 72.88% of
women presented before age 85. MCC was the first malignancy diagnosed in 66.23% of men
& 75.44% of women. The most common location was the face (23.77% of men & 29.37% of
women), and most common stage at presentation was localized (46.69% of men & 51.67% of
women). Relative survival rates at 1, 3, and 5 years were 83.8%(95% CI 82.40-85.10),
63.40%(95% CI 61.50-65.30), & 56.20%(95% CI 53.90-58.40) in men & 87.20%(95% CI
85.60-88.70), 74.40%(95% CI 72.00-76.50), & 70.10%(95% CI 67.30-72.70) in women.
Death due to MCC occurred in 29.44% of men & 21.08% of women. Conclusion: Our results
elucidate differences in MCC survival between the sexes and reveal that women may have
more favorable prognoses with significantly higher relative survival rates at 1, 3, and 5 years.

Analyzing the impact of COVID-19 on trends in the dermatology literature
R Ali, S Prasad, R Singh, L Abdelrahman, R Kankaria, S Singh, S Mehta, V Mroz and E
Freeman Dermatology, Massachusetts General Hospital, Boston, Massachusetts, United
States
Intro: For the past two years, the COVID-19 pandemic has significantly impacted scientific
publishing across medical specialties. We sought to characterize the rising body of evidence
related to COVID-19 within the dermatology literature since March 2020, the WHO-declared
start of the pandemic. Methods: We extracted all publications indexed in PubMed from
March 11, 2020 to Sept 31, 2021, from the four highest impact factor journals in dermatology: Journal of the American Academy of Dermatology (JAAD), JAMA Dermatology
(JAMADerm), British Journal of Dermatology (BJD), and Journal of Investigative Dermatology
(JID). Rapid communications were excluded. Titles & abstracts of all publications were
reviewed to determine relevance to COVID-19; articles were then classified by publication
type and category of COVID-19 related content. Results: Of 3,649 publications, 335 were
COVID-19 related (9%). Of these 335 publications, content focused on: cutaneous manifestations of COVID (32%), other diseases in the time of COVID (28%), practice management
(11%), PPE/occupational health (10%), medical education (8%), vaccines (5%), pathophysiology (3%), impact of COVID on research (2%), and disparities (1%). In the first three-month
period of the pandemic, 95 COVID related articles were published, the majority of which
were research letters (18(19%)) followed by editorials (12(13%)). In the following three-month
period (June-Aug 2020), 93 articles were published, primarily research letters (23(25%))
followed by original articles (3(3%)). Conclusion: The rapid rise in COVID-related dermatologic publications within the first few months of the pandemic mirrors the trend seen in
other specialties. COVID-19 related articles now comprise a significant share of the dermatologic literature and cover a range of topics in pandemic response beyond characterization
of SARS-CoV-2 itself.

www.jidonline.org S29

